Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
- James, N D
- Sydes, M R
- Clarke, N W
- Mason, M D
- Dearnaley, D P
- Spears, M R
- Ritchie, A W S
- Parker, C C
- Russell, J M
- Attard, G
- de Bono, J
- Cross, W
- Jones, R J
- Thalmann, G
- Amos, C
- Matheson, D
- Millman, R
- Alzouebi, M
- Beesley, S
- Birtle, A J
- Brock, S
- Cathomas, R
- Chakraborti, P
- Chowdhury, S
- Cook, A
- Elliott, T
- Gale, J
- Gibbs, S
- Graham, J D
- Hetherington, J
- Hughes, R
- Laing, R
- McKinna, F
- McLaren, D B
- O'Sullivan, J M
- Parikh, Oi
- Peedell, C
- Protheroe, A
- Robinson, A J
- Srihari, N
- Srinivasan, Rajaguru
- Staffurth, J
- Sundar, S
- Tolan, S
- Tsang, D
- Wagstaff, J
- Parmar, M K B
DOIAbstract
Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.The article is available via Open Access. Click on the 'Additional Link' above to access the full-text
Add to ORKG